Biolidics (SGX:8YY) has addressed queries from the Singapore Exchange regarding its recent issuance of 946 million new ordinary shares, according to a Monday filing on the Singapore Exchange.
Shares of the medical technology company were allocated to vendors Yuan Zhijun and Wu Kunwei before the completion of a proposed acquisition.
The company explained that the early issuance was necessitated by the listing and quotation notice's requirement to issue shares within seven market days.
Additionally, the timing was influenced by anticipated delays in securing approvals from Chinese regulatory authorities due to the Golden Week holiday.
The issuance aims to prevent potential mandatory takeover obligations under Singapore's Takeovers Code, ensuring that the subscription does not trigger such a requirement.
All acquisition conditions have been fulfilled, with the completion expected around Oct. 25, pending further approvals from PRC governmental agencies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.